Logo image of GELS

GELTEQ LTD (GELS) Stock Fundamental Analysis

NASDAQ:GELS - Nasdaq - AU0000218109 - Common Stock - Currency: USD

1.2799  -0.05 (-3.77%)

Fundamental Rating

1

Overall GELS gets a fundamental rating of 1 out of 10. We evaluated GELS against 192 industry peers in the Pharmaceuticals industry. GELS has a bad profitability rating. Also its financial health evaluation is rather negative. GELS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GELS has reported negative net income.
In the past year GELS has reported a negative cash flow from operations.
GELS Yearly Net Income VS EBIT VS OCF VS FCFGELS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -1M -2M -3M

1.2 Ratios

Looking at the Return On Assets, with a value of -17.08%, GELS is in the better half of the industry, outperforming 66.15% of the companies in the same industry.
With a decent Return On Equity value of -23.47%, GELS is doing good in the industry, outperforming 70.31% of the companies in the same industry.
Industry RankSector Rank
ROA -17.08%
ROE -23.47%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GELS Yearly ROA, ROE, ROICGELS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -5 -10 -15

1.3 Margins

GELS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GELS Yearly Profit, Operating, Gross MarginsGELS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

GELS does not have a ROIC to compare to the WACC, probably because it is not profitable.
GELS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GELS Yearly Shares OutstandingGELS Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2M 4M 6M 8M
GELS Yearly Total Debt VS Total AssetsGELS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of 0.65, we must say that GELS is in the distress zone and has some risk of bankruptcy.
GELS's Altman-Z score of 0.65 is in line compared to the rest of the industry. GELS outperforms 56.25% of its industry peers.
GELS has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.12, GELS perfoms like the industry average, outperforming 46.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 0.65
ROIC/WACCN/A
WACC9.14%
GELS Yearly LT Debt VS Equity VS FCFGELS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

GELS has a Current Ratio of 0.08. This is a bad value and indicates that GELS is not financially healthy enough and could expect problems in meeting its short term obligations.
GELS has a worse Current ratio (0.08) than 96.35% of its industry peers.
A Quick Ratio of 0.08 indicates that GELS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.08, GELS is doing worse than 96.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08
GELS Yearly Current Assets VS Current LiabilitesGELS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 200K 400K 600K 800K 1M

More info and screens

0

3. Growth

3.1 Past

GELS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.13%.
The Revenue for GELS has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-1.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.62%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GELS Yearly Revenue VS EstimatesGELS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 50K 100K
GELS Yearly EPS VS EstimatesGELS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GELS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GELS Price Earnings VS Forward Price EarningsGELS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GELS Per share dataGELS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GELS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GELTEQ LTD

NASDAQ:GELS (3/7/2025, 8:00:01 PM)

1.2799

-0.05 (-3.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.86%
Inst Owner ChangeN/A
Ins Owners48.88%
Ins Owner ChangeN/A
Market Cap12.08M
AnalystsN/A
Price TargetN/A
Short Float %0.52%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS1.01
TBVpS-0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.08%
ROE -23.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z 0.65
F-Score2
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.62%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.53%
OCF growth 3YN/A
OCF growth 5YN/A